Accolate captures 3.4% of new asthma controller scripts; Zeneca Zoladex sales gain 57%.

Executive Summary

ZENECA ACCOLATE GARNERS 3.4% OF ASTHMA CONTROLLER NEW RXs BY JANUARY, three months after its October launch, according to Scott Levin's Rx Watch. In January, "Accolate captured nearly 4% of the new retail dollars," Scott-Levin stated. "Its share has steadily increased since it was launched." Scott-Levin calculated that Accolate produced 41,000 new prescriptions in January, generating $2.2 mil. retail dollars. Primary care physicians wrote 50% of January Accolate prescriptions, followed by pulmonary disease specialists, with 22% of scripts, and allergists, with 16%. The agent's share among pulmonary and allergy specialists was "considerably higher than its 3.4% share overall," Scott-Levin commented.